Compared with monoclonal antibodies, peptide ligands, which have the advantages of rapid tissue penetration, faster blood clearance, easy incorporation into certain delivery vectors and low immunogenicity are being pursued as targeting moieties for the selective delivery of radionuclides cytokines, chemical drugs, or therapeutic genes to tumors [15]. This effect may open up diagnostic procedures and therapeutic options for the patient. Identification of the cancer cell receptors that binds the ZT-2 peptide would allow further improvement of the

peptide for potential clinical use. These preliminary experiments provide evidence that the ZT-2 BLZ945 peptide may be specific to A498 and therefore it would be useful for diagnosis of renal carcinoma or delivery of an antitumor therapeutic agent. Studies are continuing to identify the cellular receptors responsible for peptide binding and to apply the peptide to clinically relevant samples. Acknowledgements This work was supported by National Natural Science Foundation of China (No.81172432), The Project Supported by Guangdong Natural Science Foundation of the People’s Republic of China (No.9151802904000002), selleck chemical Scientific and Technical Project of Guangdong Province of the People’s Republic of China (2008B030301082), Doctoral Initiating Project,

and Natural Scientific Foundation of Guangdong Province of the People’s Republic of China (No.7301521) References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, CA Cancer. J Clin 2009

2009,59(4):225–249. 2. Zhang J, Huang YR, Liu DM, Zhou LX, Xue W, Chen Q, Dong BJ, Pan JH, Xuan HQ: Management of solid renal tumour associated with von Hippel-Lindau disease. Chin Med J 2007,120(22):2049–2052.PubMed 3. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001,345(23):1655–1659.PubMedCrossRef 4. Cohen HT, McGovern FJ: Renal-cell carcinoma. aminophylline N Engl J Med 2005,353(23):2477–2490.PubMedCrossRef 5. Tunuguntla HS, Jorda M: Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008,179(6):2096–2102.PubMedCrossRef 6. Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009,55(4):851–863.PubMedCrossRef 7. Pande J, selleck products Szewczyk MM, Grover AK: Phage display: concept, innovations, applications and future. Biotechnol Adv 2010,28(6):849–858.PubMedCrossRef 8. Barry MA, Dower WJ, Johnston SA: Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide presenting phage libraries.